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S U M M A R Y
Inﬂammation is a double-edged sword in the outcome of pneumonia. On the one hand, an effective and
timely inﬂammatory response is required to eliminate the invading respiratory pathogen. On the other, a
toxic and prolonged inﬂammatory response may result in lung injury and poor outcomes, even in those
receiving advanced medical care. This review focuses on recent understanding of the dynamics of the
cytokine response, neutrophil activity, and responsiveness to cytokines and neutrophil lifespan as major
elements of lung inﬂammation resulting in favorable or poor outcomes in lung infection primarily due to
pneumococcus and inﬂuenza virus. Although some progress has been made in our understanding of the
molecular mechanisms of the pneumonia inﬂammation axis composed of cytokines modulating
neutrophil activation and neutrophil apoptosis, important questions remain to be answered. The degree
of neutrophil activation, generation of reactive oxygen species, and the release of granule antimicrobial
peptides play a key role in microbial pathogen clearance; however, prolonged neutrophil activation may
contribute to lung injury and poor outcomes in pneumonia. Molecular markers of the mechanisms
regulating neutrophil survival and apoptosis may help in the identiﬁcation of novel therapeutic targets
to modulate inﬂammation by inducing timely neutrophil apoptosis. A major task is to identify the
mechanisms of dysregulation in inﬂammation leading to toxic responses, thereby targeting a biomarker
and enabling timely therapies to modulate inﬂammation.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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1.1. The burden of pneumonia
Pneumonia accounts for a death toll greater than the combined
mortalities due to malaria, tuberculosis, and AIDS.1 A lack of
appropriate management of the toxic inﬂammatory response
remains a serious limitation in the medical management of
bacterial and viral inﬂuenza pneumonia. The latter is illustrated by
a mortality of about 50% in patients with severe pneumonia,
despite receiving advanced medical treatment.2 These results* Corresponding author.
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http://dx.doi.org/10.1016/j.ijid.2012.06.006demand further research to better understand the mechanisms
and factors regulating the host inﬂammatory response that lead to
the poor outcomes associated with pneumonia.
1.2. The normal inﬂammation process in pneumonia
Pneumonia is an exuberant sequestration of peripheral
neutrophils in the lungs, which is tightly regulated by cascades
of cytokines produced by the immune system in response to an
invading pathogen.3 A network of cytokine signals plays an
essential role in the modulation of the inﬂammatory response,
the clearance of the pathogen, and the subsequent repair of the
lung tissue. In pneumonia, as alveolar macrophages fail to
control the invading pathogens, cytokines and chemokines are
released in order to attract neutrophils to the affected lungses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Proposed mechanism for the cytokine storm and poor clinical outcomes in community-acquired pneumonia (CAP) patients with deleterious inﬂammation.
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transition to cells primed for enhanced responses and ﬁnally to
fully activated cells. Activated neutrophils engulf and sequester
microorganisms through phagocytosis and kill ingested bacteria
by a combination of the production of toxic oxygen radicals,
proteolytic enzymes, myeloperoxidase, defensins, and other
bactericidal peptides. The degree of neutrophil activation,
generation of reactive oxygen species (ROS), and the release of
granule proteins play a key role in microbial pathogen clearance.
In the ideal scenario, the acute lung inﬂammation is protective
and self-limited, and once the infection has been controlled,
cytokines also function to restore homeostasis, including the
modulation of neutrophil apoptosis.7 On the other hand, a
cytokine storm results in a deleterious inﬂammation and poor
clinical outcome (Figure 1).
1.3. Unmet needs in understanding the inﬂammation process in
pneumonia
The many acute lung inﬂammation-related factors responsible
for lung injury and poor outcomes in pneumonia are not yet fully
understood.8 Data from the pre-antibiotic era indicate that the
lung inﬂammatory response to Streptococcus pneumoniae is
sufﬁcient to protect a substantial number of patients.9,10 This
massive pulmonary inﬂammatory response has been considered
‘beneﬁcial’, but it is now clear that in some patients it persists and
evolves into a systemic toxic inﬂammatory response, leading to
organ failure.11,12 In severe pneumonia, such persistent and toxic
inﬂammation leads to an overly pro-inﬂammatory cytokine
balance, characterized by sustained high levels of tumor necrosis
factor (TNF), neutrophil hyper-responsiveness, and dysregulation
of lung neutrophil apoptosis, all major factors leading to lung
injury and poor patient outcomes.13,14 Consequently, efforts to
improve the management of patients with pneumonia need to
consider the host response factors, including the identiﬁcation of
biomarkers that might predict a poor patient outcome. In this
regard, determination of the blood neutrophil phenotype in
relation to cytokine proﬁle, as well as assessment of blood
neutrophil responsiveness and lung neutrophil apoptosis in
relation to the degree of lung injury and clinical outcome should
be instrumental in gaining an insight into both factors driving the
toxic lung inﬂammation of community-acquired pneumonia (CAP)
and potential therapeutic options.From a translational research perspective, we reviewed studies
of cytokines, neutrophil function, and neutrophil apoptosis
modulating both the host inﬂammatory response and the out-
comes of patients with CAP. A PubMed search was done using the
phrases ‘‘cytokine and pneumonia’’, ‘‘neutrophil and pneumonia’’,
and ‘‘neutrophil apoptosis and pneumonia’’ for the years 1980–
2011. Other relevant papers on these topics dated earlier than 1980
were also included. This review examines the role of cytokines,
neutrophil activity, and neutrophil apoptosis in the inﬂammatory
response in pneumonia, with special emphasis on pneumococcal
and inﬂuenza virus infections. We also describe some of our
laboratory ﬁndings, relating inﬂammation to the clinical outcomes
of patients with CAP.
2. Role of cytokines in the inﬂammatory response in
pneumonia
2.1. Pro- and anti-inﬂammatory cytokines
The exact role of each speciﬁc cytokine in the inﬂammatory
response during pneumonia is still a subject of ongoing research.
Although it is generally possible to classify cytokines into two
groups based on their predominant function, i.e., pro-inﬂammato-
ry cytokines (such as interleukin (IL)-1b, IL-1a, IL-6, IL-8 (CXCL8),
IL-17, macrophage inﬂammatory proteins (MIP-1 (CCL3), MIP-1
(CCL4)), and TNF-a) and anti-inﬂammatory cytokines (such as IL-4,
IL-10, and transforming growth factor (TGF)-b),15–17 it is impor-
tant to point out that this classiﬁcation is not absolute, as many
cytokines are capable of exerting both pro-inﬂammatory and anti-
inﬂammatory effects depending on a variety of factors, such as the
immunological and clinical contexts. During the initial phases of
pneumonia, alveolar macrophages produce a variety of pro-
inﬂammatory cytokines and chemokines whose role is to both
attract and activate polymorphonuclear leukocytes necessary for
local bacterial defense and clearance.18,19 Thus, circulating levels of
pro-inﬂammatory cytokines, including TNF-a, IL-1, IL-6, IL-8, IL-
12, and interferon gamma (IFN-g), are usually found to be elevated
in patients with CAP.11,20,21 In addition to these ‘classical pro-
inﬂammatory cytokines’, members of the IL-17/IL-23 axis have
also been shown to play an important role in modulating airway
inﬂammatory responses by regulating the expression and the pro-
inﬂammatory versus tissue-protective properties of another
cytokine, IL-22.22,23
Table 1
Cytokine concentration ratios in sputum vs. plasmaa
Sputum/plasma ratio
>1000 100–200 1–20 <1
IL-1b IFN-g IP-10 IL-10
IL-1ra IL-6 IL-17 IL-12p70
IL-8 TNF-a
IL, interleukin; IFN-g, interferon-gamma; IP-10 interferon gamma-induced protein
10; TNF-a, tumor necrosis factor alpha.
a Ratios in the table were calculated by dividing the concentration in sputum
(in pg/ml) by the concentration in plasma (in pg/ml) for each cytokine.
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surprising that inﬂammation is a tightly balanced process. In the
context of infection, the pro-inﬂammatory cytokine response is
normally regulated by the anti-inﬂammatory components of the
immune system. However, if this balance cannot be achieved or
becomes altered, deleterious effects can result for the whole
organism.24,25 Cytokines such as IL-10 and IL-4 play an anti-
inﬂammatory role, inhibiting cytokine production and other pro-
inﬂammatory functions by macrophages.12 Indeed, IL-10 has been
demonstrated as a key regulator of the degree of lung inﬂamma-
tion. For example, decreased IL-10 concentrations in bronchoal-
veolar lavage (BAL) ﬂuid have been associated with a worse
outcome in patients with acute respiratory distress syndrome
(ARDS), presumably due to excessive inﬂammation.26 Accordingly,
it has been proposed that IL-10 could be a beneﬁcial adjunctive
therapy to antibiotics against pneumococcal pneumonia.27
Although most investigators tend to view cytokine responses in
terms of pro- and anti-inﬂammatory balance, this is not the only
interpretation. In contrast to the conventional interpretation of
immunologic dissonance, deﬁned as preponderance of either pro-
inﬂammatory or anti-inﬂammatory cytokine responses, Kellum et
al. have suggested that different patterns of cytokine response could
best be described based on their concentrations as high, medium,
and low, rather than their pro- or anti-inﬂammatory activities.28
2.2. Cytokine production: the role of the bug
Although there is no clear relationship between the local
bacterial burden and the intensity of the elicited inﬂammation, it
has been suggested that the host immune response to CAP and the
magnitude of cytokine secretion vary depending on the causative
microorganism involved.12,21,22 A recent review from Paterson and
Orihuela showed that a variety of pro-inﬂammatory cytokines (IL-6,
IL-12, IL-17, and IL-18) are important mediators in the innate
response to pneumococci.29 Their concentrations in serum are
usually higher in pneumococcal pneumonia than in non-pneumo-
coccal lung infection.30 In addition, TNF-a has also been reported to
be a critical factor in the protective response against pneumococci.31
These ﬁndings are supported by experimental evidence that deletion
or neutralization of TNF-a has deleterious effects and by the ﬁnding
that human patients treated with anti-TNF-a therapies suffer an
increased risk of invasive pneumococcal disease.30 It is important to
remark that while a pro-inﬂammatory cytokine response is essential
in the response to pneumococcal pneumonia, the same cytokines
can cause deleterious effects if the response becomes excessive or
not adequately balanced by anti-inﬂammatory mechanisms.
Pro-inﬂammatory cytokine responses are also essential during
immune responses to inﬂuenza pneumonia, but an overly aggressive
and dysregulated cytokine response, known as a ‘cytokine storm’,
has been associated with inﬂuenza-related morbidity and mortality,
particularly in avian H5N1 inﬂuenza.32 Several studies have recently
been conducted in order to better understand the inﬂammatory
response during inﬂuenza H1N1 virus infection. Patients with
inﬂuenza pneumonia had signiﬁcantly higher serum levels of
cytokines than those without a lung infection,33 presumably due to
the hyper-reactivity of immune cells in response to acute lung
injury.34 Consistent with the general ﬁndings in CAP, disease
severity was associated with pronounced impairment of the host
immune response.35 Furthermore, apart from tissue damage caused
by the virus lytic replication, lung damage can be worsened by an
imbalanced overproduction of antiviral cytokines. In this regard,
Pinto et al. demonstrated that virus titers and pro-inﬂammatory
cytokine expression can be modulated simultaneously, providing a
new potential therapy against viral pneumonia.36
In an elegant paper, Mene´ndez and co-workers showed that
different inﬂammatory patterns are elicited by microorganismsand that this ﬁnding may provide a useful tool for both diagnosis
and treatment.37 Finally, understanding the different cytokine
responses elicited by different pathogens is crucial because, as was
suggested by McConnell et al., targeting speciﬁc host inﬂamma-
tory responses (induced by each pathogen) could represent a new
potential therapeutic approach in sepsis.38
2.3. Cytokine timing and decompartmentalization
In addition to antibiotic therapy, the inﬂammatory response,
over time, is crucial to control the infection and eradicate the
pathogen in pneumonia. Mean cytokine concentrations are
generally highest on admission and they decline rapidly over
the ﬁrst few days.24,28 It has been proven that IL-1, IL-6, IL-8, and
IL-10 act as acute-phase proteins, decreasing rapidly after
admission, in contrast to the more blunt kinetics of C-reactive
protein.30 However, the circulating cytokine response during
pneumonia remains a heterogeneous process and continues for
more than a week after presentation, with considerable overlap
between those who do and those who do not develop severe
sepsis.28 In an ongoing study by our group comparing cytokine
proﬁles in patients differing in ‘time to clinical stability’ (TCS)
following hospital admission, we found that although the levels of
pro-inﬂammatory (IL-6, IL-8, IL-12) and anti-inﬂammatory (IL-10)
cytokines were generally high on admission (day 1) for all patients,
there was a sharp decrease in those with an early TCS (>3 days),
but a plateau in those with a late TCS (>3 days).
In pneumonia the host response is generally compartmental-
ized, with markedly different concentrations of inﬂammatory
mediators – cytokines included – in the lungs versus the systemic
circulation.38 TNF-a and IL-6 act as general markers of inﬂamma-
tion in pneumonia and regulate the expression of acute-phase
proteins, thus integrating systemic response and local injury.19,39–
41 Despite this compartmentalization, Calbo et al. demonstrated
that in patients with severe pneumococcal pneumonia, pro- and
anti-inﬂammatory responses could be detected in venous blood,
representing a systemic extension of the compartmentalized
response, where each cytokine showed a similar pattern of decline,
with progressive normalization accompanied by clinical recovery,
suggesting that this phenomenon is a part of the homeostatic
response to the infection.20 Moret et al. have recently hypothe-
sized that inﬂammatory resolution can proceed at different rates,
being slower in lung compared to the systemic compartment.42 In
an ongoing study comparing cytokine levels in plasma vs. sputum
samples from pneumonia patients, our group has observed that
although the levels of most cytokines are higher in the latter,
different cytokines can be grouped based on their relative
concentration ratios between the two types of samples (e.g.,
sputum/plasma). For example, these ratios were >1000-fold
higher for IL-1b, IL-1ra, and IL-8, whereas <1 for IL-10 and IL-12
in sputum vs. plasma (see Table 1). These results suggest that there
is not only true compartmentalization but preferential cytokine
secretion locally vs. systemically.
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There is increasing evidence that an adequate cytokine balance
plays a crucial role in determining outcomes in hospitalized patients
with pneumonia.25 Different markers of severity of the disease such
as confusion, hypotension, pleural effusion, and bacteremia have
been associated with excesses of both pro- and anti-inﬂammatory
cytokines, particularly IL-6 and IL-10.22,24,43,44 Serum IL-6 correlates
best with both disease-speciﬁc and generic severity scores and may
therefore be a valid marker of inﬂammation and prognosis in
CAP.21,24A systemic inﬂammation characterized by an increase in IL-
6 and IL-10 has also been correlated with delayed clinical stability,
while pre-antibiotic treatment as well as pneumococcal vaccination
seem to be protective factors for excess of IL-6 and IL-10.42,43
The evaluation of circulating cytokine concentrations could
help in predicting the risk of potential complications in CAP. A
persistent, up-regulated, pro-inﬂammatory response is associated
with deaths due to cardiovascular disease, renal failure, infection,
and cancer, whereas persistent low-grade inﬂammation and
immune suppression may play an important role in coronary
events, cerebrovascular events, and repeat bouts of CAP.45–49
Patients who have persistent elevation of cytokines have a higher
risk of dying, and mortality seems to be correlated with the ratio of
IL-6 to IL-10.22,43,50,51 However, some authors suggest that even if
plasma levels of IL-6 strongly predict outcomes, they are probably
not actually correlated to mortality.51,52 Cytokine levels might
actually be more predictive of adverse outcomes when measured
at the end of hospitalization, rather than on admission.28 This
hypothesis is supported by the strong association between
elevated circulating IL-6 concentrations and higher mortality over
the subsequent 3 months after discharge.45 In the same way, serum
TNF-a levels can be useful in identifying patients at risk of
functional impairment following hospitalization with CAP.53
A recent study was conducted by our group based on the
hypothesis that gradients of pro- and anti-inﬂammatory cytokines
in blood and in exhaled breath condensate correlate with the degree
of lung injury and clinical outcome of patients with CAP.54,55 A
negative correlation was found between the IL-10/IL-6 ratio and TCS
(r = 0.372, p = 0.014), as well as IL-4/IL-6 ratio and TCS (r = 0.312,
p = 0.042). These ﬁndings may be due to the balancing role of anti-
inﬂammatory cytokines. An effective anti-inﬂammatory response
seems to be a protective factor, whilst individuals showing
unbalanced pro-inﬂammatory patterns take a longer time to
recover. Cytokine production may also vary according to the
individual’s characteristics including age, smoking status, and co-
existing medical conditions. Kelly et al. found that advanced age was
not associated with blunting of the systemic cytokine response,
although in well-functioning, elderly subjects, pre-infection sys-
temic levels of TNF-a and IL-6 were associated with a higher risk of
CAP requiring hospitalization in smokers and in those with
coexisting medical conditions.56 Inﬂammatory responses in immu-
nocompromised patients are still not completely understood. In
Pneumocystis jiroveci pneumonia, the concentrations of monocyte
chemotactic protein-1/2 (MPC-1/2) (CCL2/CCL8), IL-8, and IL-6
differed according to the underlying disease, tending to be higher in
patients with autoimmune disease and lower in those with AIDS.57
Moreover, it was recently demonstrated that local TNF-a production
is reduced in neutropenic patients, which may be a signiﬁcant factor
determining the severity of pneumonia and a possible reason for the
poor prognosis in these patients.58
2.5. Modulation of pro-inﬂammatory cytokine production and clinical
outcomes
Because of the key importance of the inﬂammatory response in
the outcome of pneumonia, anti-inﬂammatory therapies havebeen considered to have potential beneﬁcial effects. Based on their
well-established inhibitory effects on the production of a variety of
pro-inﬂammatory cytokines such as TNF-a, IL-1, IL-2, IL-6, and IL-
8, the use of glucocorticoids has been promoted as adjunctive
therapy in severe pneumonia. The effectiveness of glucocorticoid
treatment in pneumonia, however, has remained somewhat
controversial, in part because of its added immunosuppressive
and other effects, particularly after prolonged administration.
Some reports seem to support a sort of modulation of the
inﬂammatory response in severe CAP by short-term administra-
tion of glucocorticoids, with a favorable impact in terms of
accelerating the time to resolution of symptoms, length of stay in
the intensive care unit, and mortality.59,60 On the other side, a
different experience suggested no evidence of a beneﬁcial effect of
corticosteroids in patients with ARDS secondary to inﬂuenza
pneumonia.61 Additional studies are needed to more completely
characterize and optimize the therapeutic potential of glucocorti-
coids in pneumonia.
3. Role of neutrophils in the inﬂammatory response in
pneumonia
3.1. Neutrophil strategies to combat the infection
Neutrophils have evolved different strategies and mechanisms
to combat an infection. These cells have the ability to kill
microorganisms both by the production of ROS and by the release
of antibacterial and lytic enzymes inside the phagosome.62
Additionally, neutrophils can release their genomic DNA and, in
combination with elastase and other antimicrobial granule
proteins, generate a net called a DNA-based neutrophil extracellu-
lar trap (NET) that will trap and kill microbial pathogens.63 Besides
the ability of neutrophils to kill microbial pathogens, these cells
can release granule components and a variety of cytokines and
chemokines resulting in the recruitment and activation of other
cells of the immune system, such as monocytes, dendritic cells, and
T-cells, which provide evidence for the key role that neutrophils
play in the regulation of the host immune response.64–67
Neutrophils have four different types of granules: secretory
vesicles, gelatinase, speciﬁc, and azurophilic granules, which are
differentiated based on their protein content and separation by a
density gradient fractionation.67,68 The release of the different
neutrophil granules is sequential during the inﬂammatory
response. The secretory vesicles are the ﬁrst granules to undergo
exocytosis and they allow neutrophils to adhere and roll through
the endothelial monolayer in the blood vessels. Release of
gelatinase granules will follow, allowing neutrophils to transmi-
grate into the site of infection. Once the neutrophils arrive at the
site of inﬂammation, speciﬁc and azurophilic granule proteins
come out to support bacterial killing by the release of antimicrobial
proteins.69–71
3.2. Neutrophil activation and migration
After initiation of a bacterial infection, a number of chemokines,
cytokines, and chemoattractants are released by surrounding cells,
which activate neutrophils that are present in the circulation
during rest such that their harmful intracellular granule contents
are not accidentally released to damage host tissue.67 In patients
with pneumonia, one of the primary defense mechanisms is the
migration of neutrophils into the alveolar space. In the course of
this migration process, neutrophils change their phenotype from a
resting circulating cell into a prime cell. Additionally, resting
neutrophils can be primed by bacterial products: cytokines and
chemokines including IL-8, IFN-g, TNF-a, granulocyte macrophage
colony-stimulating factor (GM-CSF), and platelet activating factor
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increase in the respiratory burst response when they encounter a
second stimulus at the site of inﬂammation, such as the bacterial
wall component N-formyl-methionyl-leucyl-phenylalanine
(fMLF).73
Activation of neutrophils by priming agents is an advantageous
process to clear infection, but uncontrolled ROS production and
release of bactericidal proteins from the neutrophil granules can
result in organ damage. We have recently shown that exocytosis of
neutrophil granules plays a critical role in TNF-a-induced priming.
Blocking secretory vesicle, speciﬁc granule, and gelatinase granule
exocytosis by introduction of a TAT-SNAP-23 fusion protein
reduced phagocytosis-stimulated hydrogen peroxide production
without affecting phagocytosis or bacterial killing inside the
phagosome.74
It has been reported that patients with severe sepsis have a
primed population of neutrophils.14 Priming of ROS production is
involved in many human diseases. Ex vivo stimulation of
neutrophils from ARDS patients showed that those cells were
hyper-responsive with the ability to produce high levels of ROS.
Additionally, it was shown that the hyper-responsiveness of
neutrophils derived from ARDS patients correlated with high
plasma levels of TNF-a. In summary, TNF-a-primed neutrophils
may play a major role in the pathogenesis of ARDS-associated lung
injury.13 Understanding the mechanisms that regulate neutrophil
granule exocytosis in primed cells during infection can provide
new insights into potential therapeutic options to control
neutrophil activation during inﬂammation.
We are currently conducting a translational study to evaluate
the degree of the neutrophil functional response over time in the
blood and the lungs of hospitalized patients with CAP. Blood and
sputum samples from CAP patients have been collected at different
time points after hospitalization. Different neutrophil function
assays such as exocytosis of the four different granule subsets,
phagocytosis, respiratory burst activity, and apoptosis have been
evaluated in both blood and sputum samples. Basal levels for each
of the neutrophil functional assays have been determined using
whole blood from healthy donors. Our preliminary results indicate
that a prolonged, primed neutrophil phenotype in the circulation,
accompanied by low plasma levels of IL-6 and IL-1b, result in a
delay to clinical stability in patients with CAP (S.M. Uriarte et al.,
manuscript in preparation).
4. Role of neutrophil apoptosis in the inﬂammatory response in
pneumonia
Neutrophils are terminally differentiated cells and have a very
short lifespan. They are viable in the circulation for 8–10 h before
they succumb to cell death. It is very important to maintain the
cellular homeostasis of neutrophils. It has been shown that under
physiological conditions the turnover rate for neutrophils is
equivalent to the production of these cells from the bone
marrow, which will constitute the circulating neutrophil
population, and the rate of neutrophils utilized in the tissue.75
Constitutive neutrophil death occurs in the absence of extracel-
lular stimuli and this is the essential mechanism to maintain
neutrophil homeostasis. Increased rates of neutrophil death can
cause neutropenia by decreasing neutrophil counts. This can
augment the chances of contracting bacterial and fungal
infections. Moreover, delayed neutrophil death causes neutro-
philia by increasing neutrophil counts; this is associated with
increased inﬂammation after infection. Thus, maintaining
appropriate neutrophil numbers or neutrophil homeostasis is
critical during infection and/or inﬂammation. During infection or
inﬂammation, the neutrophil lifespan is prolonged or neutrophil
death is delayed to combat infection and inﬂammation.76However, delayed neutrophil apoptosis can cause tissue damage
by generation of ROS. Delayed neutrophil death can be
modulated by induction of apoptosis or necrosis. It has been
shown that apoptotic or necrotic neutrophils release a-defen-
sins, which have anti-inﬂammatory properties on macrophages
by inhibiting the release of pro-inﬂammatory cytokines without
affecting their antimicrobial activity.77 Thus, mechanisms that
lead to timely induction of apoptosis are critical in resolving the
inﬂammatory response.7
Once neutrophils undergo apoptosis, they express phosphati-
dylserines on the outer leaﬂet of the cells so that they are
recognized and cleared by scavenger macrophages.78 The ideal
scenario for resolution of inﬂammation is the termination of
neutrophil activation by induction of neutrophil apoptosis after
they phagocytose dead bacteria. Neutrophil apoptosis occurs
without release of harmful granule contents. However, during
infection or inﬂammation the neutrophil lifespan is prolonged and
the continued generation of superoxide radicals by these activated
neutrophils may cause tissue damage to surrounding normal
tissue. When phagocytosis is impaired, neutrophils undergo
necrosis. Necrotic cell death is accompanied by release of harmful
granule contents that further damage healthy tissue and exacer-
bate the inﬂammatory response by recruiting additional inﬂam-
matory cells into the site of infection. Thus, uncontrolled
neutrophil activation, by delay of neutrophil apoptosis and
inadequate resolution of inﬂammation, plays a critical role in
the tissue injury associated with septic multi-organ failure
syndrome, ischemia–reperfusion injury observed in myocardial
infarction, stroke, and acute tubular necrosis, as well as immune
complex-mediated diseases.79–84
For complete resolution of inﬂammation to occur, apoptotic
neutrophils have to be cleared by macrophages thereby
preventing release of toxic neutrophil granule proteins and
preserving the host tissue. Clearance of apoptotic neutrophils
can occur both at the systemic level and at the tissue level.
Circulating neutrophils will be cleared in the liver, spleen, and
bone marrow, while apoptotic tissue neutrophils will be cleared
by local tissue macrophages. However, if either neutrophil
apoptosis or clearance of apoptotic neutrophils by macrophages
is delayed, inﬂammation-related tissue damage occurs. In some
scenarios, neutrophil clearance is not delayed, likely because of
the presence of speciﬁc cytokines and/or a pro-inﬂammatory
milieu resulting in an exacerbation of inﬂammation by macro-
phages presenting neutrophils to the T-cells as non-self.
Neutrophil apoptosis may also not be delayed but dysregulated
or compensated by the neutrophil NETosis or autophagy
modulating neutrophil proteins, leading to presentation of these
neutrophil-modulated proteins by antigen presenting cells to T-
cells as non-self antigens, leading to stimulation of the immune
system and exacerbation of inﬂammation. It is therefore
important to understand the mechanisms that regulate neutro-
phil apoptosis. This phenomenon seems straightforward, but if
either neutrophil apoptosis is delayed or the clearance of
apoptotic neutrophils by macrophages is delayed, this leads to
exacerbation of inﬂammation.
There are two distinct pathways that contribute to apoptosis:
intrinsic and extrinsic apoptotic pathways. The extrinsic pathway
is the death receptor pathway activated by Fas (TNF-a) and TNF-
related apoptosis-inducing ligand (TRAIL).85 Ligation of the death
receptors at the cell surface leads to the formation of death-
inducing signaling complex (DISC), involving adaptor proteins
such as Fas-associated death domain (FADD) and activation of
caspase 8.86 The intrinsic pathway is a mitochondrial pathway
stimulated by cell stressors such as UV radiation, heat shock,
growth factor withdrawal, osmotic shock, DNA damage, and
chemotherapeutic drugs. The intrinsic pathway is mediated
Figure 2. Increased ERK phosphorylation (IB: pERK) and no caspase 3 activation in
neutrophils obtained from a patient sputum on day 1 (D1), indicative of increased
neutrophil survival and activation. Sputum neutrophils from the same patient on
day 3 (D3) demonstrate increased caspase 3 activation and abrogation of ERK
phosphorylation, indicative of termination of neutrophil activation and induction of
neutrophil apoptosis.
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transmembrane potential, release in cytochrome C and apoptosis-
inducing factor, assembly of the apoptosome, and ﬁnally, the
activation of caspase 3.87,88 Both the extrinsic and intrinsic
pathways culminate in activation of caspases, which are known to
cleave intracellular proteins resulting in the death of the cell.
Neutrophil apoptosis is tightly regulated by a complex network
of signaling pathways that control activation and inactivation of
Bcl2 family proteins, including anti-apoptotic proteins A1 and Bcl-
xL, Mcl-1, and pro-apoptotic proteins Bad, Bid, Bak, and Bax.
Removal of activated neutrophils by apoptosis is a signiﬁcant
mechanism by which the inﬂammatory response is appropriately
terminated.
Extensive work has been done on the involvement of several
kinases that regulate neutrophil survival. Pro-survival kinases
MAPK/ERK and PI-3K/Akt have been shown to regulate neutrophil
survival.87 Thus, ERK phosphorylation is a marker of neutrophil
activation or survival and active caspase 3 is a marker of neutrophil
apoptosis.
Pneumonia is also associated with neutrophil activation in
the sputum and BAL ﬂuid. Spontaneous apoptosis of sputum
neutrophils in pneumonia patients is markedly reduced in non-
responding CAP, while it is increased in responding CAP patients,
allowing resolution of inﬂammation in the responding group.42
The Community-Acquired Pneumonia Inﬂammatory Study
Group (CAPISG) evaluated neutrophil activation in the sputum
of CAP patients. The inﬂammatory response was correlated with
clinical outcomes in CAPISG patients. In one patient who was
conﬁrmed to have inﬂuenza A H3N2 pneumonia by nucleic acid
ampliﬁcation tests for respiratory viruses, on day 1 (D1) of
admission, we demonstrated increased ERK phosphorylation
and no caspase 3 activation in neutrophils obtained from the
sputum of this patient (Figure 2). The data are indicative of
increased neutrophil survival and activation. On day 3 (D3),
sputum neutrophils obtained from the same patient demon-
strated increased caspase 3 activation and abrogation of ERK
phosphorylation, indicative of termination of neutrophil activa-
tion and induction of neutrophil apoptosis (Figure 2). Therefore,
it is critical to identify signaling proteins within the complex
network of proteins that cross-talk with one another to either
promote neutrophil survival or neutrophil apoptosis. The
identiﬁcation of such proteins may lead to the discovery of
novel therapeutic targets to control inﬂammation by inducing
timely neutrophil apoptosis.5. Conclusions
There is substantial growing knowledge of the causal effect of
the toxic inﬂammatory response in the poor outcomes of severe
pneumonia managed with appropriate medical care. A prolonged
toxic inﬂammatory response is primarily driven by a dysregula-
tion of cytokine cascades, neutrophil hyperactivity, and in-
creased neutrophil survival, resulting in lung injury. The degree
of neutrophil activation, generation of ROS, and the release of
granule proteins, all play a key role in microbial pathogen
clearance; however, prolonged neutrophil activation may
contribute to lung injury and poor patient outcomes. Molecular
markers of regulation of neutrophil survival and neutrophil
apoptosis may lead to the discovery of novel therapeutic targets
to modulate inﬂammation by inducing timely neutrophil
apoptosis. A major task is to identify early cytokine dysregula-
tion leading to a toxic inﬂammatory response, thereby targeting
a biomarker and enabling timely therapies to modulate
inﬂammation.
Conﬂict of interest: No conﬂict of interest to declare.
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